These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35931078)

  • 1. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
    Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
    Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
    Zhang XH; Wei H; Xia Y; Morad M
    Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
    Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
    J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
    Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
    Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
    PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of the calcium release channel deficiency syndrome.
    Tester DJ; Kim CSJ; Hamrick SK; Ye D; O'Hare BJ; Bombei HM; Fitzgerald KK; Haglund-Turnquist CM; Atkins DL; Nunez LAO; Law I; Temple J; Ackerman MJ
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32663189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca
    Yamaguchi N; Zhang XH; Morad M
    Methods Mol Biol; 2022; 2573():41-52. PubMed ID: 36040585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.
    Fatima A; Xu G; Shao K; Papadopoulos S; Lehmann M; Arnáiz-Cot JJ; Rosa AO; Nguemo F; Matzkies M; Dittmann S; Stone SL; Linke M; Zechner U; Beyer V; Hennies HC; Rosenkranz S; Klauke B; Parwani AS; Haverkamp W; Pfitzer G; Farr M; Cleemann L; Morad M; Milting H; Hescheler J; Saric T
    Cell Physiol Biochem; 2011; 28(4):579-92. PubMed ID: 22178870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
    Pölönen RP; Swan H; Aalto-Setälä K
    Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
    Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
    Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
    Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
    J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
    Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
    EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The V2475F CPVT1 mutation yields distinct RyR2 channel populations that differ in their responses to cytosolic Ca
    Wilson AD; Hu J; Sigalas C; Venturi E; Valdivia HH; Valdivia CR; Lei M; Musgaard M; Sitsapesan R
    J Physiol; 2021 Dec; 599(23):5179-5201. PubMed ID: 34676560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
    Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
    Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oxidation-resistant CaMKII-MM281/282VV mutation does not prevent arrhythmias in CPVT1.
    Sadredini M; Manotheepan R; Lehnart SE; Anderson ME; Sjaastad I; Stokke MK
    Physiol Rep; 2021 Sep; 9(18):e15030. PubMed ID: 34558218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.